FRANKFURT German drugmaker Bayer (BAYGn.DE) said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto (MON.N) stirred criticism it might neglect its pharmaceuticals business.
Bayer now expects annual peak sales of more than 5 billion euros ($5.6 billion) for stroke prevention pill Xarelto, jointly sold with Johnson & Johnson (JNJ.N), where it had previously seen about 3.5 billion.
23:06 AT&T discussed takeover in meetings with Time Warner: Bloomberg
05:20 Roche third-quarter sales rise 3 percent, confirms outlook
13:59 Nearly 200 Nations Agree To Cut Greenhouse Gases In Landmark Climate Change Deal
10:28 Nearly 200 nations agree binding deal to cut greenhouse gases